FDA Grants Priority Review to PADCEV-Keytruda Combination for Muscle-Invasive Bladder Cancer Treatment

Key Takeaways

• FDA grants Priority Review to Astellas’ supplemental Biologics License Application for PADCEV plus Keytruda combination therapy
• If approved, this would be the first perioperative treatment for muscle-invasive bladder cancer patients regardless of cisplatin eligibility status
• Application supported by statistically significant survival data from Phase 3 EV-304 trial, potentially establishing new standard of care

---

The U.S. Food and Drug Administration has granted Priority Review designation to Astellas Pharma’s supplemental Biologics License Application (sBLA) for PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) as a perioperative treatment for muscle-invasive bladder cancer (MIBC), the company announced April 20, 2026.

Breakthrough Treatment Potential

The regulatory submission is based on statistically significant event-free survival and overall survival data from the Phase 3 EV-304 clinical trial. This combination therapy builds upon PADCEV’s existing indication for cisplatin-ineligible MIBC patients, potentially expanding treatment options to all muscle-invasive bladder cancer patients regardless of their cisplatin eligibility status.

If approved, the PADCEV-Keytruda combination would become the first and only perioperative treatment available for the broader MIBC patient population, marking a significant advancement in bladder cancer care. The perioperative approach involves treatment both before and after surgery, aiming to improve patient outcomes by addressing cancer cells that may remain after surgical removal of the primary tumor.

Clinical Trial Success

The EV-304 trial demonstrated the combination’s efficacy in treating muscle-invasive bladder cancer patients. PADCEV, an antibody-drug conjugate developed by Astellas, works by delivering a cytotoxic payload directly to cancer cells expressing Nectin-4, a protein commonly found on bladder cancer cells. Keytruda, Merck’s PD-1 inhibitor, enhances the immune system’s ability to recognize and attack cancer cells.

The Priority Review designation, which shortens the FDA’s review timeline to six months instead of the standard ten months, reflects the potential significance of this treatment approach for patients with limited therapeutic options.

Market Impact and Patient Access

Muscle-invasive bladder cancer affects thousands of patients annually in the United States, with treatment options historically limited by patient eligibility for cisplatin-based chemotherapy. Cisplatin, while effective, cannot be used in patients with certain kidney problems, hearing issues, or other health conditions that make them ineligible for this standard treatment.

The potential approval of PADCEV plus Keytruda regardless of cisplatin eligibility could significantly expand the addressable patient population and establish a new standard of care in bladder cancer treatment. This development represents a major opportunity for Astellas to strengthen its position in the oncology market while providing physicians with more treatment options for their patients.

Regulatory Timeline

With Priority Review status, the FDA is expected to complete its evaluation by late 2026, assuming a six-month review period from the acceptance date. The agency will assess the combination’s safety and efficacy data, manufacturing information, and proposed labeling before making its approval decision.

The success of this application could pave the way for broader adoption of combination immunotherapy approaches in bladder cancer treatment and potentially influence treatment guidelines for muscle-invasive disease.

---

Frequently Asked Questions

What does Priority Review mean for patients with muscle-invasive bladder cancer?

Priority Review means the FDA will evaluate the PADCEV-Keytruda combination in six months instead of ten, potentially bringing this treatment to patients faster. If approved, it would be the first perioperative treatment available regardless of whether patients can receive cisplatin chemotherapy.

When will PADCEV plus Keytruda be available for bladder cancer patients?

With Priority Review status granted in April 2026, the FDA is expected to complete its evaluation by late 2026. However, approval is not guaranteed and depends on the agency’s assessment of the clinical trial data and safety profile.

How does this combination compare to current bladder cancer treatments?

Current perioperative treatments for muscle-invasive bladder cancer are primarily limited to cisplatin-based chemotherapy, which many patients cannot receive due to health conditions. The PADCEV-Keytruda combination would be the first option available to all MIBC patients regardless of cisplatin eligibility, potentially becoming a new standard of care.